| ➡️ Get instant news updates on Whatsapp. Click here to join our Whatsapp Group. |
The Accretion Pharmaceuticals IPO is set to open on May 14, 2025, and will close on May 16, 2025. This IPO is a Book Built Issue, with the company aiming to raise approximately ₹29.75 crores. The offering includes a fresh issue of ₹29.75 crores, along with an offer for sale of equity shares, each having a face value of ₹10.
The price band for the Accretion Pharmaceuticals IPO is ₹96 to ₹101 per share. The allocation is as follows: 35% for retail investors, 50% for Qualified Institutional Buyers (QIB), and 15% for High Net-Worth Individuals (HNI). The shares are expected to list on the NSE on May 21, 2025, with the allotment date set for May 19, 2025.
In its financial performance, the company reported a revenue of ₹33.94 crores for 2024, up from ₹29.53 crores in 2023. It also posted a profit of ₹3.88 crores in 2024, a significant rise compared to ₹0.10 crores in 2023. Based on these financials, investors are advised to consider this IPO for long-term investment.
Accretion Pharmaceuticals IPO Details
- IPO Open Date: May 14, 2025
- IPO Close Date: May 16, 2025
- Face Value: ₹10 Per Equity Share
- IPO Price Band: ₹96 to ₹101 Per Share
- Issue Size: Approximately ₹29.75 Crores
- Fresh Issue: Approximately ₹29.75 Crores
- Issue Type: Book Built Issue
- IPO Listing: NSE SME
- Retail Quota: Up to 35%
- QIB Quota: Up to 50%
- NII Quota: Up to 15%
- DRHP Draft Prospectus: Click Here
- RHP Draft Prospectus: Click Here
Accretion Pharmaceuticals IPO Market Lot
The minimum market lot for the Accretion Pharmaceuticals IPO is 1,200 shares, with an application amount of ₹1,21,200.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1,200 | ₹1,21,200 |
| Retail Maximum | 1 | 1,200 | ₹1,21,200 |
| S-HNI Minimum | 2 | 2,400 | ₹2,42,400 |
Accretion Pharmaceuticals IPO Dates
The Accretion Pharmaceuticals IPO will open on May 14, 2025, and close on May 16, 2025. The allotment will be finalized on May 19, 2025, and the shares will be listed on the NSE on May 21, 2025.
- IPO Open Date: May 14, 2025
- IPO Close Date: May 16, 2025
- Basis of Allotment: May 19, 2025
- Refunds: May 20, 2025
- Credit to Demat Account: May 20, 2025
- IPO Listing Date: May 21, 2025
Promoters of Accretion Pharmaceuticals IPO
The promoters of Accretion Pharmaceuticals are Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, and Mr. Hardik Mukundbhai Prajapati.
About Accretion Pharmaceuticals
Founded in 2012, Accretion Pharmaceuticals Limited is a prominent player in the pharmaceutical industry, engaged in the manufacturing and marketing of tablets, capsules, and other healthcare products. In addition to selling its own products, the company also provides manufacturing services for other brands through licensing agreements and contract manufacturing.
The company holds multiple certifications, reflecting its strong commitment to quality and environmental standards. Its manufacturing facility is located in Sanand, Ahmedabad, Gujarat. Accretion Pharmaceuticals has expanded its global footprint to over 20 countries, with a presence in regions like Africa, Southeast Asia, and the Middle East. As of January 2025, the company employs 83 people, including four Executive Directors.
Accretion Pharmaceuticals IPO Financial Highlights
Accretion Pharmaceuticals has shown strong financial growth over the past few years. In FY 2024, the company reported revenue of ₹33.94 crores, up from ₹29.53 crores in FY 2023. The profit after tax also saw a sharp rise, reaching ₹3.88 crores in 2024 compared to ₹0.10 crores in 2023.
Below is a summary of the company’s financial performance (amounts in ₹ crores):
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2022 | ₹22.58 | ₹783.90 | ₹0.08 | ₹17.74 |
| 2023 | ₹29.53 | ₹1,472.25 | ₹0.10 | ₹20.58 |
| 2024 | ₹33.94 | ₹2,883.26 | ₹3.88 | ₹27.05 |
| July 2024 | ₹11.89 | ₹1,423.72 | ₹1.57 | ₹29.34 |
Accretion Pharmaceuticals IPO Valuation – FY2024
Here’s a summary of Accretion Pharmaceuticals’ key financial and valuation metrics for FY2024, including details on EPS, P/E ratio, RoNW, and NAV:
| Key Performance Indicator (KPI) | Value |
|---|---|
| Return on Equity (ROE) | 72.80% |
| Return on Capital Employed (ROCE) | 36.73% |
| EBITDA Margin | 23.06% |
| PAT Margin | 11.51% |
| Debt-to-Equity Ratio | 2.52 |
| Earnings Per Share (EPS) (Basic) | ₹9.69 |
| Price/Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 72.47% |
| Net Asset Value (NAV) | ₹- |
Peer Group Comparison
Here’s a comparison of Accretion Pharmaceuticals with some of its industry peers based on key financial metrics:
| Company | EPS | P/E Ratio | RoNW (%) | NAV | Income |
|---|---|---|---|---|---|
| Sakar Healthcare Limited | ₹5.64 | 65.30 | 4.45% | ₹120.65 | – Cr. |
| Lincoln Pharmaceuticals Limited | ₹46.58 | 12.58 | 15.74% | ₹295.98 | – Cr. |
| Sotac Pharmaceuticals Limited | ₹5.24 | 23.09 | 11.91% | ₹43.69 | – Cr. |
Objects of the Issue
- Capital expenditure for purchasing new equipment and machinery
- Capital expenditure for upgrading the existing manufacturing facility
- Repayment or prepayment of certain borrowings taken by the company
- Funding working capital needs
- General corporate purposes
Accretion Pharmaceuticals IPO Review – Broker Recommendations
Here’s a list of brokerages and financial institutions that have reviewed or are expected to review the Accretion Pharmaceuticals IPO:
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Accretion Pharmaceuticals IPO Registrar
- Registrar: KFin Technologies Limited
- Phone: 040-67162222, 040-79611000
- Email: apl.ipo@kfintech.com
- Website: KFinTech IPO Status
IPO Lead Manager (Merchant Banker)
- Company: Jawa Capital Services Private Limited
Company Contact Details
- Company Name: Accretion Pharmaceuticals Limited
- Address: 29 Xcelon Ind Park 1, Behind Intas Pharmaceuticals, Vasna Chacharvad, Sanand, Gujarat
- Phone: +91-97148 82929
- Email: compliance@accretionpharma.com
- Website: Accretion Pharmaceuticals
Accretion Pharmaceuticals IPO FAQs
1. What is the Accretion Pharmaceuticals IPO?
The Accretion Pharmaceuticals IPO is an SME public offering through which the company aims to raise ₹29.75 crores. The price band for the issue is set between ₹96 and ₹101 per equity share. The shares will be listed on the NSE SME platform.
2. When does the Accretion Pharmaceuticals IPO open for subscription?
The IPO will open for subscription on May 14, 2025, for Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Investors. The subscription window will close on May 16, 2025.
3. What is the investor allocation in the Accretion Pharmaceuticals IPO?
The allocation of shares is divided as follows:
- QIBs: 50%
- NIIs (HNI category): 15%
- Retail Investors: 35%
How to Apply for the Accretion Pharmaceuticals IPO?
You can apply for the Accretion Pharmaceuticals IPO through the ASBA facility available in your bank account online. Alternatively, you can apply via UPI through your stock broker’s platform or submit an offline application form through your broker.
- 1. What is the Accretion Pharmaceuticals IPO Issue Size?
- The total issue size is ₹29.75 crores.
- 2. What is the Accretion Pharmaceuticals IPO Price Band?
- The price band is set between ₹96 and ₹101 per share.
- 3. What is the Accretion Pharmaceuticals IPO Lot Size?
- The minimum application is for 1 lot, which equals 1200 shares, amounting to ₹1,21,200.
- 4. What is the Accretion Pharmaceuticals IPO Allotment Date?
- The allotment is scheduled for May 19, 2025.
- 5. What is the Accretion Pharmaceuticals IPO Listing Date?
- The shares are expected to be listed on the NSE on May 21, 2025.